StreetInsider.com News Articles

Almirall Inaugurates Offices in China to Advance Innovation in Medical Dermatology Through Partnerships

Thu, 12 Mar 2026 03:36:00 -0400

Almirall Institutional Event Shanghai

The biopharmaceutical company’s presence in Shanghai, China is dedicated to life science innovation and business development with a focus on programs and technologies that are complementary to its in-house R&D expertise.
The successful collaboration with Simcere for the development of an interleukin 2 mutant fusion protein (IL-2muFc) initially targeting alopecia areata and atopic dermatitis is a blueprint for future collaborations.
Almirall’s commercial presence in China is expanding through a second agreement with a local partner for the commercialisation of a product for the treatment of acne.

SHANGHAI & BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A. (ALM), a global

Almirall Inaugurates Offices in China to Advance Innovation in Medical Dermatology Through Partnerships

Thu, 12 Mar 2026 03:36:00 -0400

Almirall Institutional Event Shanghai

The biopharmaceutical company’s presence in Shanghai, China is dedicated to life science innovation and business development with a focus on programs and technologies that are complementary to its in-house R&D expertise.
The successful collaboration with Simcere for the development of an interleukin 2 mutant fusion protein (IL-2muFc) initially targeting alopecia areata and atopic dermatitis is a blueprint for future collaborations.
Almirall’s commercial presence in China is expanding through a second agreement with a local partner for the commercialisation of a product for the treatment of acne.

SHANGHAI & BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A. (ALM), a global

Almirall Inaugurates Offices in China to Advance Innovation in Medical Dermatology Through Partnerships

Thu, 12 Mar 2026 03:36:00 -0400

Almirall Institutional Event Shanghai

The biopharmaceutical company’s presence in Shanghai, China is dedicated to life science innovation and business development with a focus on programs and technologies that are complementary to its in-house R&D expertise.
The successful collaboration with Simcere for the development of an interleukin 2 mutant fusion protein (IL-2muFc) initially targeting alopecia areata and atopic dermatitis is a blueprint for future collaborations.
Almirall’s commercial presence in China is expanding through a second agreement with a local partner for the commercialisation of a product for the treatment of acne.

SHANGHAI & BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A. (ALM), a global

Almirall Inaugurates Offices in China to Advance Innovation in Medical Dermatology Through Partnerships

Thu, 12 Mar 2026 03:36:00 -0400

Almirall Institutional Event Shanghai

The biopharmaceutical company’s presence in Shanghai, China is dedicated to life science innovation and business development with a focus on programs and technologies that are complementary to its in-house R&D expertise.
The successful collaboration with Simcere for the development of an interleukin 2 mutant fusion protein (IL-2muFc) initially targeting alopecia areata and atopic dermatitis is a blueprint for future collaborations.
Almirall’s commercial presence in China is expanding through a second agreement with a local partner for the commercialisation of a product for the treatment of acne.

SHANGHAI & BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A. (ALM), a global

Almirall Inaugurates Offices in China to Advance Innovation in Medical Dermatology Through Partnerships

Thu, 12 Mar 2026 03:36:00 -0400

Almirall Institutional Event Shanghai

The biopharmaceutical company’s presence in Shanghai, China is dedicated to life science innovation and business development with a focus on programs and technologies that are complementary to its in-house R&D expertise.
The successful collaboration with Simcere for the development of an interleukin 2 mutant fusion protein (IL-2muFc) initially targeting alopecia areata and atopic dermatitis is a blueprint for future collaborations.
Almirall’s commercial presence in China is expanding through a second agreement with a local partner for the commercialisation of a product for the treatment of acne.

SHANGHAI & BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A. (ALM), a global

Almirall Inaugurates Offices in China to Advance Innovation in Medical Dermatology Through Partnerships

Thu, 12 Mar 2026 03:36:00 -0400

Almirall Institutional Event Shanghai

The biopharmaceutical company’s presence in Shanghai, China is dedicated to life science innovation and business development with a focus on programs and technologies that are complementary to its in-house R&D expertise.
The successful collaboration with Simcere for the development of an interleukin 2 mutant fusion protein (IL-2muFc) initially targeting alopecia areata and atopic dermatitis is a blueprint for future collaborations.
Almirall’s commercial presence in China is expanding through a second agreement with a local partner for the commercialisation of a product for the treatment of acne.

SHANGHAI & BARCELONA, Spain--(BUSINESS WIRE)-- Almirall, S.A. (ALM), a global

Almonty Industries (ALM) PT Raised to $25 at DA Davidson

Fri, 06 Mar 2026 08:52:50 -0400

DA Davidson analyst Matt Summerville raised the price target on Almonty Industries (NASDAQ: ALM) to $25.00 (from $18.00) while maintaining a Buy rating.

The analyst commented, "Later today, we expect the Fastmarkets price fix for the week to eclipse $2,000/MTU, amid what we now view as a supply crisis, we are updating the pricing assumptions embedded in our multi-asset ALM model. In short, we are marking our C1Q26 model slightly above the YTD avg. spot price (per Fastmarkets), while materially raising our base price that informs our model through ‘28. In our view, global mined output supply is beyond constrained, with

Almonty Industries (ALM) PT Raised to $25 at DA Davidson

Fri, 06 Mar 2026 08:52:50 -0400

DA Davidson analyst Matt Summerville raised the price target on Almonty Industries (NASDAQ: ALM) to $25.00 (from $18.00) while maintaining a Buy rating.

Almonty Industries (ALM) PT Raised to $17 at B.Riley

Tue, 03 Mar 2026 08:38:53 -0400

B.Riley raised its price target on Almonty Industries (NASDAQ: ALM) to $17.00 (from $6.00) while maintaining a Buy rating.

Couloir Capital is Pleased to Announce That it Has Updated its Research Coverage on Almonty Industries

Tue, 24 Feb 2026 08:45:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - February 24, 2026) - Couloir Capital is pleased to announce that it has updated its research coverage on Almonty Industries Inc. (TSX: AII) (NASDAQ: ALM) (ASX: AII) (FSE: ALI1) (or "Company"). Couloir Capital's Research Team crafted a report titled "Higher Tungsten Prices Trigger Revaluation; Sangdong Ramp on Track; Maintain Hold."

Report excerpt: "Tungsten market fundamentals have strengthened materially, supported by higher benchmark APT prices that have recently moved above US$1,000/MTU amid robust defence-driven demand and a tightening supply environment. China's export controls implemented in 2025 have reinforced structural supply constraints

Couloir Capital is Pleased to Announce That it Has Updated its Research Coverage on Almonty Industries

Tue, 24 Feb 2026 08:45:00 -0400

Almirall eczema drug beats forecasts, 2026 guidance flags margin turn

Mon, 23 Feb 2026 04:05:10 -0400

Investing.com -- Almirall SA’s eczema biologic Ebglyss tripled sales in its second year on the European market and edged past analyst forecasts, the Barcelona-based dermatology specialist said on Monday, as the company’s 2026 profit guidance signalled the first signs of meaningful margin expansion from the drug’s growing contribution.

Ebglyss, approved for moderate-to-severe atopic dermatitis, generated €110.8 million in net sales in 2025, up more than threefold year-on-year and 3% above company-compiled consensus of €107.6 million.

Almirall has set a peak sales target for the product of above €450

Almirall’s 2025 Results

Mon, 23 Feb 2026 01:06:00 -0400

Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe

Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory.
This revenue growth further advances Almirall’s leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM).
The continued strong

Almirall’s 2025 Results

Mon, 23 Feb 2026 01:06:00 -0400

Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe

Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory.

This revenue growth further advances Almirall’s leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM).

The continued strong

Almirall’s 2025 Results

Mon, 23 Feb 2026 01:06:00 -0400

Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe

Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory.

This revenue growth further advances Almirall’s leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM).

The continued strong

Almirall’s 2025 Results

Mon, 23 Feb 2026 01:06:00 -0400

Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe

Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory.

This revenue growth further advances Almirall’s leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM).

The continued strong

Almirall’s 2025 Results

Mon, 23 Feb 2026 01:06:00 -0400

Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe

Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory.

This revenue growth further advances Almirall’s leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM).

The continued strong

Almirall’s 2025 Results

Mon, 23 Feb 2026 01:06:00 -0400

Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe

Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory.

This revenue growth further advances Almirall’s leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM).

The continued strong

Almirall’s 2025 Results

Mon, 23 Feb 2026 01:06:00 -0400

Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe

Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory.

This revenue growth further advances Almirall’s leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM).

The continued strong

Almirall’s 2025 Results

Mon, 23 Feb 2026 01:06:00 -0400

Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe

Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory.

This revenue growth further advances Almirall’s leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM).

The continued strong

Almirall’s 2025 Results

Mon, 23 Feb 2026 01:06:00 -0400

Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe

Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory.

This revenue growth further advances Almirall’s leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM).

The continued strong

Almirall’s 2025 Results

Mon, 23 Feb 2026 01:06:00 -0400

Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe

Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory.

This revenue growth further advances Almirall’s leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM).

The continued strong

Critical Minerals Surge: Here Are Five Companies Mining Tungsten, Copper, and Silver

Thu, 19 Feb 2026 10:15:00 -0400

Issued on behalf of GoldHaven Resources Corp.
VANCOUVER, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- EquityInsider.com News Commentary — The United States is converting critical minerals policy into capital at unprecedented speed. Project Vault, a landmark public-private initiative backed by a $10 billion Export-Import Bank loan and $2 billion in private capital, aims to build a civilian strategic minerals reserve covering 60 commodities classified as critical by the USGS^[1]. Simultaneously, physical silver investment is forecast to surge 20% in 2026 to a three-year high of 227 million ounces, even as the market heads into its

Critical Minerals Surge: Here Are Five Companies Mining Tungsten, Copper, and Silver

Thu, 19 Feb 2026 10:15:00 -0400

Issued on behalf of GoldHaven Resources Corp.
VANCOUVER, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- EquityInsider.com News Commentary — The United States is converting critical minerals policy into capital at unprecedented speed. Project Vault, a landmark public-private initiative backed by a $10 billion Export-Import Bank loan and $2 billion in private capital, aims to build a civilian strategic minerals reserve covering 60 commodities classified as critical by the USGS^[1]. Simultaneously, physical silver investment is forecast to surge 20% in 2026 to a three-year high of 227 million ounces, even as the market heads into its

Critical Minerals Surge: Here Are Five Companies Mining Tungsten, Copper, and Silver

Thu, 19 Feb 2026 10:15:00 -0400

Issued on behalf of GoldHaven Resources Corp.
VANCOUVER, British Columbia, Feb. 19, 2026 (GLOBE NEWSWIRE) -- EquityInsider.com News Commentary — The United States is converting critical minerals policy into capital at unprecedented speed. Project Vault, a landmark public-private initiative backed by a $10 billion Export-Import Bank loan and $2 billion in private capital, aims to build a civilian strategic minerals reserve covering 60 commodities classified as critical by the USGS^[1]. Simultaneously, physical silver investment is forecast to surge 20% in 2026 to a three-year high of 227 million ounces, even as the market heads into its